drugset / Trial / NCT02403505
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer
Phase 1
Active not recruiting
20 enrolled
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
UnitedHealthcare · collab
NaSingle-groupOpen-labelHealth-services research
Summary
Conducting an early phase clinical trial to assess CEA Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of CEA positive rectal cancer patients. 1. Treat CEA positive rectal cancer via Trained Immunity. 2. Activate human CEA Protein Antigen Presentation Reaction. 3. The human antigen presenting cells (APCs) can treat the CEA protein antigen into small peptide fragments, and then kill CEA positive rectal cancer cells in vivo.
Timeline
- Start
- 2021-12-28
- Primary completion
- 2026-11-28
- Completion
- 2026-12-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCG vaccine | Vaccine | 50 mg | Other |
| Subject | CEA protein antigen | Protein / enzyme biologic | 0.05 mg | Other |